Taken together, these results show that PRKCSH contributes to the adaptation of tumor cells against TNFSF cytotoxicity by increasing the half-life of IGF1R, which is involved in tumor resistance to antitumor immunity and various cancer therapeutics. Here, IGF1R is linked to neoplasm.